Catapult Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoetis
ZTS
|
+$23.2M |
| 2 |
PepsiCo
PEP
|
+$13.1M |
| 3 |
AbbVie
ABBV
|
+$10.1M |
| 4 |
Elevance Health
ELV
|
+$9.59M |
| 5 |
Abbott
ABT
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$22.4M |
| 2 |
Pfizer
PFE
|
+$18M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$13.1M |
| 4 |
Pediatrix Medical
MD
|
+$11.2M |
| 5 |
Danaher
DHR
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.68% |
| 2 | Consumer Discretionary | 8.46% |
| 3 | Industrials | 7.26% |
| 4 | Consumer Staples | 5.08% |
| 5 | Communication Services | 3.79% |
Similar funds
Catapult Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Catapult Capital Management held 329 positions worth $696M, down 15% from $818M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Catapult Capital Management withdrew a net $135M in Q2 2015, closing 111 positions and reducing 64 holdings. Its most notable exit was Pfizer, an estimated $18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Catapult Capital Management opened a new position in Zoetis worth $23.5M.
- Catapult Capital Management's largest Q2 2015 buy was Zoetis: 486,665 shares worth $23.5M.
- Catapult Capital Management added most to AbbVie in Q2 2015, an estimated $10.1M increase.
- Catapult Capital Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $22.4M.
- Catapult Capital Management fully exited Pfizer in Q2 2015, selling an estimated $18M.
- Catapult Capital Management's ten largest holdings make up 24% of its $696M portfolio in Q2 2015.
- Catapult Capital Management opened 119 new positions and closed 111 in Q2 2015.
- Catapult Capital Management's portfolio value fell 15% quarter-over-quarter to $696M.
Based on Catapult Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.